Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,392.00-3.13%ETH$2,560.34-5.60%GOLD$4,116.70-1.68%OIL$89.92+0.54%
Smart Investors Daily
SID Premium
CN

NASDAQ · CNTX

Context Therapeutics Inc.

Healthcare · Biotechnology

$0.32

Down-$0.01 (-4.37%)

Updated Oct 7, 2026, 1:19 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
94.64M
P/E ratio
-2.87
Dividend yield
0.00%
52-week range
$0.30 – $3.62
Volume
898.95K
Avg. volume
402.34K

Price performance · CNTX

CNTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

CNTX closed at $0.32 after 21 trading sessions, down 14.48% for the selected period.

Last close
$0.32
Period change
-14.48%
Period low
$0.30
Period high
$0.39
Daily close
View OHLC price history
CNTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$0.3389$0.3615$0.3184$0.3218898.95K
Oct 5, 2026$0.31$0.34$0.3098$0.33651M
Oct 2, 2026$0.3123$0.317$0.3032$0.3097332.65K
Oct 1, 2026$0.309$0.3199$0.2992$0.31441.14M
Sep 30, 2026$0.331$0.331$0.2965$0.30041.19M
Sep 29, 2026$0.3227$0.3316$0.3117$0.319849.45K
Sep 28, 2026$0.3493$0.3493$0.3205$0.32631.55M
Sep 25, 2026$0.3712$0.3802$0.3445$0.34571.33M
Sep 24, 2026$0.38$0.389$0.3627$0.3711883.67K
Sep 23, 2026$0.39$0.3953$0.3701$0.38261.11M
Sep 22, 2026$0.3887$0.3967$0.37$0.3891539.3K
Sep 21, 2026$0.3788$0.3879$0.3639$0.3746770.21K
Sep 18, 2026$0.3893$0.40$0.3681$0.36811.21M
Sep 17, 2026$0.374$0.3881$0.36$0.38341.51M
Sep 16, 2026$0.37$0.39$0.3601$0.3792.13M
Sep 15, 2026$0.3643$0.383$0.3512$0.36441.38M
Sep 14, 2026$0.35$0.3844$0.35$0.3512.01M
Sep 11, 2026$0.379$0.379$0.3434$0.3504829.84K
Sep 10, 2026$0.373$0.3732$0.3598$0.3664740.63K
Sep 9, 2026$0.3763$0.3798$0.37$0.37648.01K
Sep 8, 2026$0.3598$0.378$0.3502$0.37631.1M

Latest CNTX news

The latest Smart Investors Daily articles mentioning CNTX.

Stock researchCompany · Overview

CNTX research

Overview

Company profile and research snapshot.

Company profile

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.25
Implied upside
—
Analysts
—
CNTX recent ratings
DateFirmRatingTarget
Jun 16, 2026Maxim GroupBuy—
Mar 24, 2026D. Boral CapitalBuy—
Mar 24, 2026Piper SandlerOverweight—
Mar 24, 2026GuggenheimBuy—
Dec 22, 2025Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the P

Benzinga · Aug 6, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) stock rose

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By